接受索磷布韦/维帕他韦治疗的慢性丙型肝炎患者免疫检查点TIM-3、PD-1表达情况及临床意义

肝脏 ›› 2023, Vol. 28 ›› Issue (12): 1455-1458.

接受索磷布韦/维帕他韦治疗的慢性丙型肝炎患者免疫检查点TIM-3、PD-1表达情况及临床意义

童毅, 胡素侠, 王然, 戴京京

223300 江苏南京医科大学附属淮安第一医院检验科(童毅,王然,戴京京);232000 安徽安徽理工大学第一附属医院(淮南市第一人民医院)检验科(胡素侠)

收稿日期:2023-07-13 出版日期:2023-12-31 发布日期:2024-03-01
通讯作者: 戴京京,Email:hayydaijj@njmu.edu.cn
基金资助:
安徽省教育厅2021年高等学校省级质量工程项目(2021jyxm0386)

Expression of TIM-3 and PD-1 at immune checkpoint in patients with chronic hepatitis C treated with sophobuvir/Vipartamivir and its clinical significance

TONG Yi¹, HU Su-xia², WANG Ran¹, DAI Jing-jing¹

Department of Laboratory, Huai'an First Hospital Affiliated to Nanjing Medical University, Jiangsu 223300, China; Department of Laboratory, the First Affiliated Hospital of Anhui University of Technology (the first People's Hospital of Huainan), Anhui 232000, China

Received:2023-07-13 Online:2023-12-31 Published:2024-03-01
Contact: DAI Jing-jing, Email: hayydaijj@njmu.edu.cn

摘要/Abstract

摘要： 目的观察接受索磷布韦维帕他韦治疗的慢性丙型肝炎(CHC)患者免疫检查点T细胞免疫球蛋白黏蛋白3(TIM-3)、程序性细胞死亡受体-1(PD-1)的表达及临床价值。方法选择2020年8月—2022年8月南京医科大学附属淮安第一医院收治的120例CHC患者作为CHC组,另选取同期于本院体检的118例研究对象,将其作为健康对照组,CHC组给予CHC组患者索磷布韦/维帕他韦治疗,连续治疗3个月。比较两组血生化指标、单核亚群细胞以及各亚群TIM-3、PD-1水平进行检测。结果未进行治疗时,CHC患者血清ALT、AST水平分别为[(74.0±35.8)U/L、(55.1±26.0)U/L]相较于健康对照组[(14.9±6.3)U/L、(19.2±7.0)U/L]显著升高;在治疗3个月末,CHC患者PD-1 CD4、PD-1 CD8、TIM-3 CD8、TIM-3 CD4水平分别为[(0.6±0.1)%、(1.7±0.6)%、(2.5±1.0)%、(6.5±1.0)%]比对照组[(0.4±0.1)%、(1.5±0.7)%、(1.7±0.8)%、(6.0±2.4)%]高(均P<0.05)。结论索磷布韦/维帕他韦治疗CHC,有助于患者肝功能的改善,而CHC患者存在外周血部分淋巴细胞比例紊乱,负性免疫检查点分子的高表达可对细胞免疫进行调控,对于单药治疗未见症状改善的患者,可在应用索磷布韦治疗的基础上加用维帕他韦治疗。

关键词: 慢性丙型肝炎, 索磷布韦, 维帕他韦, T细胞免疫球蛋白黏蛋白3, 程序性细胞死亡受体-1

Abstract: Objective To investigate the expression and clinical significance of immunoglobulin mucin 3 (TIM-3) and programmed cell death receptor-1 (PD-1) in immune checkpoint T cells of chronic hepatitis C (CHC) patients treated with sofosbuvir/velpatasvir.Methods Between August 2020 and August 2022, 120 patients with CHC in Huai'an First Hospital Affiliated to Nanjing Medical University were selected as the CHC group, while 118 healthy individuals who underwent physical examination in the same period were selected as the healthy control group. The CHC group was treated with sofosbuvir/velpatasvir for 3 months. Blood biochemical indexes, monocyte subsets, and the levels of TIM-3 and PD-1 in each subgroup were compared between the two groups.Results In the absence of treatment, serum ALT and AST levels in CHC patients [(74.0±35.8) U/L, (55.1±26.0) U/L] were higher than those in healthy control group [(14.9±6.3) U/L, (19.2±7.0) U/L]. After three months of treatment, the PD-1 CD4, PD-1 CD8, TIM-3 CD8, TIM-3 CD4 in CHC patients [(0.6 ± 0.1) %, (1.7 ± 0.6) %, (2.5 ± 1.0) %, (6.5 ± 1.0) %, respectively] were higher than those in the healthy control group [(0.4 ± 0.1) %, (1.5 ± 0.7) %, (1.7 ± 0.8) %, (6.0 ± 2.4) %] (P<0.05).Conclusion Therapy with sophobuvir/velpatasvir can significantly improve liver function in CHC patients. The peripheral blood lymphocyte ratio is disturbed in CHC patients, and the high expression of negative immune checkpoint molecules has been observed to regulate cellular immunity. For patients who do not experience symptom improvement with single drug therapy, the addition of sofosbuvir to velpatasvir therapy may be a potential consideration.

Key words: Chronic hepatitis C, Sofosbuvir, Velpatasvir, T cell immunoglobulin mucin 3, Programmed cell death receptor-1

童毅, 胡素侠, 王然, 戴京京. 接受索磷布韦/维帕他韦治疗的慢性丙型肝炎患者免疫检查点TIM-3、PD-1表达情况及临床意义[J]. 肝脏, 2023, 28(12): 1455-1458.

TONG Yi, HU Su-xia, WANG Ran, DAI Jing-jing. Expression of TIM-3 and PD-1 at immune checkpoint in patients with chronic hepatitis C treated with sophobuvir/Vipartamivir and its clinical significance[J]. Chinese Hepatolgy, 2023, 28(12): 1455-1458.

参考文献

[1] Isakov V, Paduta D, Viani RM et al. Ombitasvir/paritaprevir/ritonavir plus dasabuvir plus ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV)[J]. Eur J Gastroenterol Hepatol,2018,30(9):1073-1076.
[2] Hsieh YC, Jeng WJ, Huang CH, et al. Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis[J]. PLoS ONE,2018,13(8):e0202777.
[3] Liu CH, Su TH, Liu CJ, et al. Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan[J]. J Formos Med Assoc;119(12):1871-1875.
[4] Dookie RS, Villegas-Mendes A, Kroeze H, et al. Combinatorial Tim-3 and PD-1 activity sustains antigen-specific Th1 cell numbers during blood-stage malaria[J]. Parasite Immunol,2020,42(9):e12723.
[5] Zahran AM, Hetta F, Rayan A, et al. Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes[J]. Cancer Immunol Immunother,2020,69(7):1253-1263.
[6] 中华预防医学会医院感染控制分会,中华医学会感染病学分会,中华预防医学会感染病防控分会. 中国丙型病毒性肝炎医院感染防控指南[J]. 传染病信息,2013,26(2):71-75.
[7] 冯凯, 黄平, 柯柳, 等. 达诺瑞韦联合索磷布韦治疗慢性丙型肝炎的真实世界临床研究[J]. 实用医学杂志,2021,37(18):2418-2422.
[8] 付婧婕, 张苑玲, 蔡秋红, 等. 索磷布韦维帕他韦片治疗慢性丙肝的临床研究[J]. 重庆医科大学学报,2020,45(10):1464-1468.
[9] Wilton J, Wong S, Yu A, et al. Real-world effectiveness of sofosbuvir / velpatasvir for treatment of chronic cepatitis C in British Columbia, Canada: a population-based cohort study[J]. Open Forum Infect Dis,2020,29,7(3):ofaa055.
[10] Marin-Acevedo JA, Dholaria B, Soyano AE, et al. Next generation of immune checkpoint therapy in cancer: New developmentsand challenges[J]. Hematol Oncol,2018,(1):39.
[11] Oh S, Lee JH, Kwack K, et al. Natural killer cell therapy: a new treatment paradigm for solid tumors[J]. Cancers,2019,11(10):E1534.
[12] 袁园, 陈继中, 朱亦林, 等. 恶性实体肿瘤患者外周血T细胞中PD-1、LAG-3、TIM-3的表达情况[J]. 安徽医科大学学报,2020,55(10):1597-1605.
[13] Tu L, Guan R, Yang H, et al. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival[J]. Int J Cancer,2020,147(2):423-439.
[14] Ghosh S, Travers J, Mceachern K, et al. Abstract 2722: Investigation of the expression profile and functional role of PD-1, TIM-3 and LAG-3 in human tumors[J]. Cancer Res,2018,78(13):2722-2722.
[15] Seguro FS , Maciel FV , Lopes GO , et al. Lymphocyte subpopulations and expression of immune checkpoint receptors PD-1 and Tim-3 in patients with chronic myeloid leukemia in a discontinuation trial[J]. Blood,2019,134(Supplement_1):1651-1651.
[16] 喻雪琴, 张诗琬, 陈芳, 等. HBV相关性肝病患者外周血PBMCs表面Tim-3、PD-1表达水平检测及意义[J]. 中国现代医学杂志,2019,29(19):43-47.